Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma
Cancers · 16.11.2026 · 18 (22) · 3659
DOI: 10.3390/cancers18223659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 16.11.2026. Verfasst von Adel Shahnam und 19 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The incidence and risk factors for central nervous system (CNS) metastases in soft tissue sarcoma (STS) are poorly defined. We evaluated the frequency of CNS metastases in STS and associated clinicopathologic and genomic factors.
Methods
This retrospective study used the Memorial Sloan Kettering Cancer Center institutional cBioPortal database. Patients with invasive STS, including gastrointestinal stromal tumor, were included. CNS metastases were identified using natural language processing-derived radiology annotations and confirmed by manual chart review. Cumulative incidence was estimated with death as a competing event. Clinicopathologic and genomic associations were evaluated using Firth logistic regression with correction for multiplicity; post-CNS metastasis survival was estimated using Kaplan–Meier analysis.
Results
A total of 5379 patients were included. CNS metastases were identified in 161 patients (3.0%), with a 10-year cumulative incidence of 4.5% after accounting for death as a competing event. Median overall survival after CNS metastasis was 4.76 months (95% CI, 3.9–7.5). In one-versus-rest analyses, increased odds of CNS metastasis were observed for alveolar soft part sarcoma (OR 16.61, 95% CI 7.21–35.81; q < 0.001), rhabdomyosarcoma (OR 2.44, 95% CI 1.42–3.97; q = 0.007), non-uterine leiomyosarcoma (OR 2.24, 95% CI 1.45–3.34; q = 0.003), extremity primaries (OR 2.20, 95% CI 1.58–3.05; q < 0.001), head and neck primaries (OR 2.11, 95% CI 1.26–3.35; q = 0.017), and PDGFRB alterations (OR 4.90, 95% CI 2.29–9.41; q = 0.016). KIT alterations were associated with lower odds (OR 0.10, 95% CI 0.02–0.29; q < 0.001).
Conclusions
CNS metastases in STS were uncommon but associated with poor survival, with risk varying by histology and primary site.
Zitieren
APA
Shahnam, A., DiConza, K., Desir-Camille, R., Jee, J., Reinhorn, D., Babatunde, O., Kelly, C. M., Saoud, C., Singer, S., Crago, A. M., Chi, P., Movva, S., Dickson, M. A., Gounder, M. M., Keohan, M. L., Maki, R. G., Reed, D. R., Tap, W. D., D’Angelo, S. P., & Banks, L. B. (2026). Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma. Cancers, 18(22), 3659. https://doi.org/10.3390/cancers18223659
Vancouver
Shahnam A, DiConza K, Desir-Camille R, Jee J, Reinhorn D, Babatunde O, et al. Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma. Cancers. 2026;18(22):3659. doi:10.3390/cancers18223659
BibTeX
@article{Shahnam2026,
author = {Shahnam, Adel and DiConza, Kristen and Desir-Camille, Rhoena and Jee, Justin and Reinhorn, Daniel and Babatunde, Olayode and Kelly, Ciara M. and Saoud, Carla and Singer, Samuel and Crago, Aimee M. and Chi, Ping and Movva, Sujana and Dickson, Mark A. and Gounder, Mrinal M. and Keohan, Mary L. and Maki, Robert G. and Reed, Damon R. and Tap, William D. and D’Angelo, Sandra P. and Banks, Lauren B.},
title = {Evaluation of the Clinicopathologic and Genomic Features of CNS Metastases in Soft Tissue Sarcoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3659},
doi = {10.3390/cancers18223659}
}
EUVIMED